Novel anti-EPHA2 antibody, DS-8895a for cancer treatment

References

• Orioli D, Klein R. The Eph receptor family: axonal guidance by contact repulsion. Trends Genet 1997; 13:354-9; PMID:9287490; http://dx.doi.org/10.1016/S0168-9525(97)01220-1
   PubMed Web of Science ®Google Scholar
• Yuan WJ, Ge J, Chen ZK, Wu SB, Shen H, Yang P, Hu B, Zhang GW, Chen ZH. Over-expression of EphA2 and EphrinA-1 in human gastric adenocarcinoma and its prognostic value for postoperative patients. Dig Dis Sci 2009; 54:2410-7; PMID:19101799; http://dx.doi.org/10.1007/s10620-008-0649-4
   PubMed Web of Science ®Google Scholar
• Saito T, Masuda N, Miyazaki T, Kanoh K, Suzuki H, Shimura T, Asao T, Kuwano H. Expression of EphA2 and E-cadherin in colorectal cancer: correlation with cancer metastasis. Oncol Rep 2004; 11:605-11; PMID:14767510; http://dx.doi.org/10.3892/or.11.3.605
   PubMed Web of Science ®Google Scholar
• Dunne PD, Dasgupta S, Blayney JK, McArt DG, Redmond KL, Weir JA, Bradley CA, Sasazuki T, Shirasawa S, Wang T, et al. EphA2 expression is a key driver of migration and invasion and a poor prognostic marker in colorectal cancer. Clin Cancer Res 2016; 22:230-42; PMID:26283684; http://dx.doi.org/10.1158/1078-0432.CCR-15-0603
   PubMed Web of Science ®Google Scholar
• Miyazaki T, Kato H, Fukuchi M, Nakajima M, Kuwano H. EphA2 overexpression correlates with poor prognosis in esophageal squamous cell carcinoma. Int J Cancer 2003; 103:657-63; PMID:12494475; http://dx.doi.org/10.1002/ijc.10860
   PubMed Web of Science ®Google Scholar
• Brannan JM, Dong W, Prudkin L, Behrens C, Lotan R, Bekele BN, Wistuba I, Johnson FM. Expression of the receptor tyrosine kinase EphA2 is increased in smokers and predicts poor survival in non-small cell lung cancer. Clin Cancer Res 2009; 15:4423-30; PMID:19531623; http://dx.doi.org/10.1158/1078-0432.CCR-09-0473
   PubMed Web of Science ®Google Scholar
• Zelinski DP, Zantek ND, Stewart JC, Irizarry AR, Kinch MS. EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res 2001; 61:2301-6; PMID:11280802
   PubMed Web of Science ®Google Scholar
• Cui XD, Lee MJ, Yu GR, Kim IH, Yu HC, Song EY, Kim DG. EFNA1 ligand and its receptor EphA2: potential biomarkers for hepatocellular carcinoma. Int J Cancer 2010; 126:940-9; PMID:19642143; http://dx.doi.org/10.1002/ijc.24798
   PubMed Web of Science ®Google Scholar
• Zeng G, Hu Z, Kinch MS, Pan CX, Flockhart DA, Kao C, Gardner TA, Zhang S, Li L, Baldridge LA, et al. High-level expression of EphA2 receptor tyrosine kinase in prostatic intraepithelial neoplasia. Am J Pathol 2003; 163:2271-6; PMID:14633601; http://dx.doi.org/10.1016/S0002-9440(10)63584-5
   PubMed Web of Science ®Google Scholar
• Thaker PH, Deavers M, Celestino J, Thornton A, Fletcher MS, Landen CN, Kinch MS, Kiener PA, Sood AK. EphA2 expression is associated with aggressive features in ovarian carcinoma. Clin Cancer Res 2004; 10:5145-50; PMID:15297418; http://dx.doi.org/10.1158/1078-0432.CCR-03-0589
   PubMed Web of Science ®Google Scholar
• Mudali SV, Fu B, Lakkur SS, Luo M, Embuscado EE, Iacobuzio-Donahue CA. Patterns of EphA2 protein expression in primary and metastatic pancreatic carcinoma and correlation with genetic status. Clin Exp Metastasis 2006; 23:357-65; PMID:17146615; http://dx.doi.org/10.1007/s10585-006-9045-7
   PubMed Web of Science ®Google Scholar
• Abraham S, Knapp DW, Cheng L, Snyder PW, Mittal SK, Bangari DS, Kinch M, Wu L, Dhariwal J, Mohammed SI. Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary bladder. Clin Cancer Res 2006; 12:353-60; PMID:16428472; http://dx.doi.org/10.1158/1078-0432.CCR-05-1505
   PubMed Web of Science ®Google Scholar
• Holm R, de Putte GV, Suo Z, Lie AK, Kristensen GB. Expressions of EphA2 and EphrinA-1 in early squamous cell cervical carcinomas and their relation to prognosis. Int J Med Sci 2008; 5:121-6; PMID:18566674; http://dx.doi.org/10.7150/ijms.5.121
   PubMedGoogle Scholar
• Merritt WM, Kamat AA, Hwang JY, Bottsford-Miller J, Lu C, Lin YG, Coffey D, Spannuth WA, Nugent E, Han LY, et al. Clinical and biological impact of EphA2 overexpression and angiogenesis in endometrial cancer. Cancer Biol Ther 2010; 10:1306-14; PMID:20948320; http://dx.doi.org/10.4161/cbt.10.12.13582
   PubMed Web of Science ®Google Scholar
• Herrem CJ, Tatsumi T, Olson KS, Shirai K, Finke JH, Bukowski RM, Zhou M, Richmond AL, Derweesh I, Kinch MS, et al. Expression of EphA2 is prognostic of disease-free interval and overall survival in surgically treated patients with renal cell carcinoma. Clin Cancer Res 2005; 11:226-31; PMID:15671550
   PubMed Web of Science ®Google Scholar
• Wang LF, Fokas E, Bieker M, Rose F, Rexin P, Zhu Y, Pagenstecher A, Engenhart-Cabillic R, An HX. Increased expression of EphA2 correlates with adverse outcome in primary and recurrent glioblastoma multiforme patients. Oncol Rep 2008; 19:151-6; PMID:18097589; http://dx.doi.org/10.3892/or.19.1.151
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhang X, Qiu Y, Huang D, Zhang S, Xie L, Qi L, Yu C, Zhou X, Hu G, et al. Clinical significance of EphA2 expression in squamous-cell carcinoma of the head and neck. J Cancer Res Clin Oncol 2011; 137:761-9; PMID:20614133; http://dx.doi.org/10.1007/s00432-010-0936-2
   PubMed Web of Science ®Google Scholar
• Straume O, Akslen LA. Importance of vascular phenotype by basic fibroblast growth factor, and influence of the angiogenic factors basic fibroblast growth factor/fibroblast growth factor receptor-1 and ephrin-A1/EphA2 on melanoma progression. Am J Pathol 2002; 160:1009-19; PMID:11891198; http://dx.doi.org/10.1016/S0002-9440(10)64922-X
   PubMed Web of Science ®Google Scholar
• Macrae M, Neve RM, Rodriguez-Viciana P, Haqq C, Yeh J, Chen C, Gray JW, McCormick F. A conditional feedback loop regulates Ras activity through EphA2. Cancer Cell 2005; 8:111-8; PMID:16098464; http://dx.doi.org/10.1016/j.ccr.2005.07.005
   PubMed Web of Science ®Google Scholar
• Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene 2007; 26:3279-90; PMID:17496922; http://dx.doi.org/10.1038/sj.onc.1210421
   PubMed Web of Science ®Google Scholar
• Koshikawa N, Hoshino D, Taniguchi H, Minegishi T, Tomari T, Nam SO, Aoki M, Sueta T, Nakagawa T, Miyamoto S, et al. Proteolysis of EphA2 converts it from a tumor suppressor to an oncoprotein. Cancer Res 2015; 75:3327-39; PMID:26130649; http://dx.doi.org/10.1158/0008-5472.CAN-14-2798
   PubMed Web of Science ®Google Scholar
• Sugiyama N, Gucciardo E, Tatti O, Varjosalo M, Hyytiäinen M, Gstaiger M, Lehti K. EphA2 cleavage by MT1-MMP triggers single cancer cell invasion via homotypic cell repulsion. J Cell Biol 2013; 201:467-84; PMID:23629968; http://dx.doi.org/10.1083/jcb.201205176
   PubMed Web of Science ®Google Scholar
• Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer 2012; 12:278-87; PMID:22437872; http://dx.doi.org/10.1038/nrc3236
   PubMed Web of Science ®Google Scholar
• Seidel UJE, Schlegel P, Lang P. Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies. Front Immunol 2013; 4:76; PMID:23543707; http://dx.doi.org/10.3389/fimmu.2013.00076
   PubMed Web of Science ®Google Scholar
• Remer M, Al-Shamkhani A, Glennie M, Johnson P. Mogamulizumab and the treatment of CCR4-positive T-cell lymphomas. Immunotherapy 2014; 6:1187-206; PMID:25496334; http://dx.doi.org/10.2217/imt.14.94
   PubMed Web of Science ®Google Scholar
• Goede V, Klein C, Stilgenbauer S. Obinutuzumab (GA101) for the treatment of chronic lymphocytic leukemia and other B-cell non-hodgkin's lymphomas: a glycoengineered type II CD20 antibody. Oncol Res Treat 2015; 38:185-92; PMID:25877943; http://dx.doi.org/10.1159/000381524
   PubMed Web of Science ®Google Scholar
• Stewart R, Hammond SA, Oberst M, Wilkinson RW. The role of Fc gamma receptors in the activity of immunomodulatory antibodies for cancer. J Immunother Cancer 2014; 2:29; http://dx.doi.org/10.1186/s40425-014-0029-x
   Google Scholar
• Trapani JA, Smyth MJ. Functional significance of the perforin/granzyme cell death pathway. Nat Rev Immunol 2002; 2:735-47; PMID:12360212; http://dx.doi.org/10.1038/nri911
   PubMed Web of Science ®Google Scholar
• DiLillo DJ, Ravetch JV. Differential Fc-receptor engagement drives an anti-tumor vaccinal effect. Cell 2015; 161:1035-45; PMID:25976835; http://dx.doi.org/10.1016/j.cell.2015.04.016
   PubMed Web of Science ®Google Scholar
• DiLillo DJ, Ravetch JV. Fc-receptor interactions regulate both cytotoxic and immunomodulatory therapeutic antibody effector functions. Cancer Immunol Res 2015; 3:704-13; PMID:26138698; http://dx.doi.org/10.1158/2326-6066.CIR-15-0120
   PubMed Web of Science ®Google Scholar
• Shields RL, Lai J, Keck R, O'Connell LY, Hong K, Meng YG, Weikert SHA, Presta LG. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem 2002; 277:26733-40; PMID:11986321; http://dx.doi.org/10.1074/jbc.M202069200
   PubMed Web of Science ®Google Scholar
• Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M, Uchida K, Anazawa H, Satoh M, Yamasaki M, et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 2003; 278:3466-73; PMID:12427744; http://dx.doi.org/10.1074/jbc.M210665200
   PubMed Web of Science ®Google Scholar
• Miao B, Ji Z, Tan L, Taylor M, Zhang J, Choi HG, Frederick DT, Kumar R, Wargo JA, Flaherty KT, et al. EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma. Cancer Discov 2015; 5:274-87; PMID:25542448; http://dx.doi.org/10.1158/2159-8290.CD-14-0295
   PubMed Web of Science ®Google Scholar
• Beck A, Reichert JM. Marketing approval of mogamulizumab: a triumph for glyco-engineering. MAbs 2012; 4:419-25; PMID:22699226; http://dx.doi.org/10.4161/mabs.20996
   PubMed Web of Science ®Google Scholar
• Niwa R, Hatanaka S, Shoji-Hosaka E, Sakurada M, Kobayashi Y, Uehara A, Yokoi H, Nakamura K, Shitara K. Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 is independent of FcgammaRIIIa functional polymorphism. Clin Cancer Res 2004; 10:6248-55; PMID:15448014; http://dx.doi.org/10.1158/1078-0432.CCR-04-0850
   PubMed Web of Science ®Google Scholar
• Terszowski G, Klein C, Stern M. KIR/HLA interactions negatively affect rituximab- but not GA101 (obinutuzumab)-induced antibody-dependent cellular cytotoxicity. J Immunol 2014; 192:5618-24; PMID:24795454; http://dx.doi.org/10.4049/jimmunol.1400288
   PubMed Web of Science ®Google Scholar
• Gerdes CA, Nicolini VG, Herter S, van Puijenbroek E, Lang S, Roemmele M, Moessner E, Freytag O, Friess T, Ries CH, et al. GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab. Clin Cancer Res 2013; 19:1126-38; PMID:23209031; http://dx.doi.org/10.1158/1078-0432.CCR-12-0989
   PubMed Web of Science ®Google Scholar
• Srivastava RM, Lee SC, Andrade Filho PA, Lord CA, Jie HB, Davidson HC, López-Albaitero A, Gibson SP, Gooding WE, Ferrone S, et al. Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients. Clin Cancer Res 2013; 19:1858-72; PMID:23444227; http://dx.doi.org/10.1158/1078-0432.CCR-12-2426
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12:252-64; PMID:22437870; http://dx.doi.org/10.1038/nrc3239
   PubMed Web of Science ®Google Scholar
• Kohrt HE, Houot R, Goldstein MJ, Weiskopf K, Alizadeh AA, Brody J, Müller A, Pachynski R, Czerwinski D, Coutre S, et al. CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood 2011; 117:2423-32; PMID:21193697; http://dx.doi.org/10.1182/blood-2010-08-301945
   PubMed Web of Science ®Google Scholar
• Kohrt HE, Houot R, Weiskopf K, Goldstein MJ, Scheeren F, Czerwinski D, Colevas AD, Weng WK, Clarke MF, Carlson RW, et al. Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. J Clin Invest 2012; 122:1066-75; PMID:22326955; http://dx.doi.org/10.1172/JCI61226
   PubMed Web of Science ®Google Scholar
• Kohrt HE, Colevas AD, Houot R, Weiskopf K, Goldstein MJ, Lund P, Mueller A, Sagiv-Barfi I, Marabelle A, Lira R, et al. Targeting CD137 enhances the efficacy of cetuximab. J Clin Invest 2014; 124:2668-82; PMID:24837434; http://dx.doi.org/10.1172/JCI73014
   PubMed Web of Science ®Google Scholar
• Takei Y, Takigahira M, Mihara K, Tarumi Y, Yanagihara K. The metastasis-associated microRNA miR-516a-3p is a novel therapeutic target for inhibiting peritoneal dissemination of human scirrhous gastric cancer. Cancer Res 2011; 71:1442-53; PMID:21169410; http://dx.doi.org/10.1158/0008-5472.CAN-10-2530
   PubMed Web of Science ®Google Scholar
• Altschul SF, Madden TL, Schäffer AA, Zhang J, Zhang Z, Miller W, Lipman DJ. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 1997; 25:3389-402; PMID:9254694; http://dx.doi.org/10.1093/nar/25.17.3389
   PubMed Web of Science ®Google Scholar
• Bendtsen JD, Nielsen H, von Heijne G, Brunak S. Improved prediction of signal peptides: SignalP 3.0. J Mol Biol 2004; 340:783-95; PMID:15223320; http://dx.doi.org/10.1016/j.jmb.2004.05.028
   PubMed Web of Science ®Google Scholar
• Krogh A, Larsson B, von Heijne G, Sonnhammer EL. Predicting transmembrane protein topology with a hidden Markov model: application to complete genomes. J Mol Biol 2001; 305:567-80; PMID:11152613; http://dx.doi.org/10.1006/jmbi.2000.4315
   PubMed Web of Science ®Google Scholar
• Marchler-Bauer A, Derbyshire MK, Gonzales NR, Lu S, Chitsaz F, Geer LY, Geer RC, He J, Gwadz M, Hurwitz DI, et al. CDD: NCBI's conserved domain database. Nucleic Acids Res 2015; 43:D222-6; PMID:25414356; http://dx.doi.org/10.1093/nar/gku1221
   PubMed Web of Science ®Google Scholar